News|Articles|October 26, 2023
Inside Look at Resilience’s Latest Viral Vector Manufacturing Site
Author(s)Resilience
Designed for advanced therapy manufacturing, the Marlborough, MA facility is the first new construction at Resilience. The site will produce, rest, and release viral vector drug substance (DS) and drug product (DP), for clinical and commercial use.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Industry Outlook 2026: Navigating AI, Sustainability, and Operational Resilience
2
Integrating AI and Machine Learning in Drug Discovery and Development
3
EMA and FDA Collaborate on Framework for AI Use in Drug Development
4
Single-Use Systems Enable Commercial-Scale CGT Manufacturing
5